Phase II study of dasatinib for CML-CP patients with suboptima/failure after treatment of imatinib

Phase II study of dasatinib for CML-CP patients with suboptima/failure after treatment of imatinib - Fukuoka CML stem cell study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004280

Enrollment

Registered

2010-09-30

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

suboptimal/failure response CML-CP patients despite imatinib treatment

Interventions

dasatib 100mg QD for CML-CP suboptimal/failure despite imatinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CML-CP suboptimal/failure despite imatinib

Exclusion criteria

Exclusion criteria: CML-BC and AP

Design outcomes

Primary

Measure	Time frame
MMR rate at 1-year after dasatinib treatment	—

Countries

Japan

Contacts

Public ContactToshihiro Miyamoto

Kyushu University Hospital Hematology & Oncology

toshmiya@intmed1.med.kyushu-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026